Naviscan readies PET biopsy
PET niche developer Naviscan arrived at the RSNA meeting with permission from the FDA to launch its Stereo Navigator, a biopsy guidance feature for its breast-specific PET scanner. Stereo Navigator can localize lesions as small as 2 mm. It uses a stereotactic frame fixed between the scanner’s paddles to guide a biopsy needle into the breast. Localization is verified using a PET-visible line source inserted into the needle track. This allows the user to confirm trajectory and position. The PET-guidance accessory is compatible with biopsy devices from Ethicon Endo-Surgery, Hologic, and SenoRx.
PET niche developer Naviscan arrived at the RSNA meeting with permission from the FDA to launch its Stereo Navigator, a biopsy guidance feature for its breast-specific PET scanner. Stereo Navigator can localize lesions as small as 2 mm. It uses a stereotactic frame fixed between the scanner's paddles to guide a biopsy needle into the breast. Localization is verified using a PET-visible line source inserted into the needle track. This allows the user to confirm trajectory and position. The PET-guidance accessory is compatible with biopsy devices from Ethicon Endo-Surgery, Hologic, and SenoRx.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
